Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide + subcutaneous daratumumab versus lenalidomide + dexamethasone in frail transplant-ineligible newly diagnosed multiple myeloma
2024-514088-25-00Phase 3Completed
- Sponsor
- CHU de Lille
- Start
- Oct 2019
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial in multiple myeloma (MM) comparing Revlimid + dexamethasone with Revlimid + Darzalex (2 arms). Primary endpoint: Progression-free survival. Started Oct 2019; status: completed.
02
Drugs
daratumumablenalidomidedexamethasone
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on 2024-514088-25-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514088-25-00.